

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	MAIL STOP RCE
)	
Nicholas S. Bodor et al.)	Group Art Unit: 1623
)	
Application No.: 10/551,205)	Examiner: JONATHAN S LAU
)	
Filed: November 14, 2006)	Confirmation No.: 4092
)	
For: ORAL FORMULATIONS OF)	
CLADRIBINE)	
)	
)	
)	

FIFTH INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98. Applicants request the Examiner's consideration of the documents listed on the accompanying Form PTO-1449.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

This Statement, Form PTO-1449 and the listed documents are submitted before the mailing of a first Office Action after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114. Continued examination is requested and the fee required under 37 C.F.R. § 1.17(e) accompanies the present submission.

These documents are not prior art. They are submitted to support positions taken and statements made at the interview of June 10, 2009, and in the accompanying Reply and Amendment.

It is respectfully requested that an Examiner-initialed copy of the accompanying Form PTO-1449 be returned to the undersigned with the next official communication.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date: July 6, 2009

By: Mary Katherine Baumeister
Mary Katherine Baumeister
Registration No. 26254

P.O. Box 1404
Alexandria, VA 22313-1404
703 836 6620